New Fund Synthesis Capital to power Australia and the Asia-Pacific’s health ventures
Posted: 11 September 2023 A new pathbreaking fund to drive the growth of Australia’s medtech and deeptech health ventures is now raising. Launched this week at the 10-year celebration of the MedTech Actuator’s pathbreaking Origin program, Synthesis Capital…
BioMedTech Horizons Program
Posted: 11 September 2023 Delivered by MTPConnect, the Australian Government’s $45 million BioMedTech Horizons program (BMTH), is a Medical Research Future Fund (MRFF) initiative to support innovative collaborative health technologies, drive discoveries towards proof-of-concept and commercialisation that address key…
Neo-Bionica Launches Hermitization Capability at Melbourne Manufacturing Headquarters
Posted: 6 September 2023 Neo-Bionica, an advanced MedTech contract manufacturer based in Melbourne, is pleased to announce the expansion of its manufacturing services with the launch of its new hermitization capability. This marks the first time that Australian…
Changes to VivaZome’s Executive and Board
Posted: 5 September 2023 VivaZome Therapeutics Pty Ltd (“VivaZome” or “Company”) is pleased to announce a suite of changes to its Executive and Board. Ms Xenia Sango has been promoted to the position of CEO and Managing Director…
New discovery: dual acting drug delivers blood cancer a lethal ‘one-two’ punch
Posted: 4 September 2023 Melbourne researchers have designed a single drug that delivers a lethal ‘one-two’ punch to several types of blood cancer in preclinical studies and could lead to improved treatments. The collaboration between medicinal chemists, laboratory and clinician scientists at…
New insights on why epilepsy develops, potential treatments in world’s largest genetic study
Posted: 4 September 2023 Specific changes in our DNA that increase the risk of developing epilepsy have been discovered, in the largest genetic study of its kind for epilepsy coordinated by the International League Against Epilepsy, which includes…
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder
Posted: 4 September 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations from its bioMUSE natural history study of Multiple…
Approval & first order for Xprecia Prime in India
Posted: 4 September 2023 Universal Biosensors, Inc. (ASX: UBI) is pleased to announce it has received approval from the Indian Central Drugs Standard Control Organisation (CDSCO) for the sale of Xprecia Prime, with the first order received from…
ENA Respiratory Expands Leadership Team and Extends U.S. Department of Defense Funding to Enable Phase II Program of INNA-051 in Community-Acquired Viral Respiratory Infections
Posted: 4 September 2023 Clinical-stage pharmaceutical company ENA Respiratory has been awarded an additional $3.8 million contract from the U.S. Department of Defence (DOD) to support ongoing research and development of INNA-051, a first-in-class, intranasal, innate immune modulator…
Could a cancer drug hold the key to a HIV cure?
Posted: 4 September 2023 An existing blood cancer drug has shown promise in killing ‘silent’ HIV cells and delaying reinfections – a significant pre-clinical discovery that could lead to a future cure for the disease. Hidden HIV cells,…
More potent treatment for a common cancer mutation provides hope
Posted: 31 August 2023 A tablet taken once a day could be a new treatment used to target one of the key drivers of cancer. Research, published in this month’s New England Journal of Medicine, has shown that divarasib,…
Avecho Conducts $6M Placement to Advance Phase III Clinical Trial
Posted: 29 August 2023 Avecho has received firm commitments to raise $6M via a Placement to support a landmark clinical study testing its proprietary TPM®-enhanced CBD soft-gel capsule for the treatment of insomnia. The Placement was conducted on the same…
